NCT00416624 · OUTCOME
Quality of Life as Measured by Brief Fatigue Inventory Overall All Follow-up Evaluations
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- units on a scale
- Interval / dispersion
- Standard Deviation
- Time frame
- Weeks 4, 7, 10, 13 and 16
What was measured
To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule. Brief Fatigue Inventory (BFI) consist of 3 single-item numeric analogue scales on a scale of 0 to 10; and an interference scale formed by 6 single-item numeric scales on a scale of 0 to 10. Higher scores indicate fatigue as bad as you can imagine for fatigue now, usual fatigue and worse fatigue; and completely interferes for BFI interference. Average scores across all time points for fatigue now, usual fatigue, worst fatigue and BFI interference subscale were calculated.
Analysis population: All patients that were evaluable per protocol with QOL data.
Groups in this outcome
Epoetin Alfa - 40k Weekly
Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)
Epoetin Alfa - 80k Every 3 Weeks
Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)
Epoetin Alfa - 120k Every 3 Weeks
Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)
Darbepoetin Alfa - 500 mcg Every 3 Weeks
Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)
| Group | Source count |
|---|---|
| Epoetin Alfa - 40k Weekly | 61 |
| Epoetin Alfa - 80k Every 3 Weeks | 60 |
| Epoetin Alfa - 120k Every 3 Weeks | 58 |
| Darbepoetin Alfa - 500 mcg Every 3 Weeks | 57 |
Reported measurements
Fatigue Now
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Epoetin Alfa - 40k Weekly | 4.8 | 2.25 | Not reported | Not reported | Not reported |
| Epoetin Alfa - 80k Every 3 Weeks | 4.6 | 2.44 | Not reported | Not reported | Not reported |
| Epoetin Alfa - 120k Every 3 Weeks | 4.6 | 2.53 | Not reported | Not reported | Not reported |
| Darbepoetin Alfa - 500 mcg Every 3 Weeks | 4.7 | 2.25 | Not reported | Not reported | Not reported |
Usual Fatigue
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Epoetin Alfa - 40k Weekly | 4.7 | 2.12 | Not reported | Not reported | Not reported |
| Epoetin Alfa - 80k Every 3 Weeks | 4.7 | 2.40 | Not reported | Not reported | Not reported |
| Epoetin Alfa - 120k Every 3 Weeks | 4.7 | 2.53 | Not reported | Not reported | Not reported |
| Darbepoetin Alfa - 500 mcg Every 3 Weeks | 4.7 | 2.24 | Not reported | Not reported | Not reported |
Worst Fatigue
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Epoetin Alfa - 40k Weekly | 5.5 | 2.17 | Not reported | Not reported | Not reported |
| Epoetin Alfa - 80k Every 3 Weeks | 5.6 | 2.54 | Not reported | Not reported | Not reported |
| Epoetin Alfa - 120k Every 3 Weeks | 5.4 | 2.60 | Not reported | Not reported | Not reported |
| Darbepoetin Alfa - 500 mcg Every 3 Weeks | 5.3 | 2.43 | Not reported | Not reported | Not reported |
BFI Interference
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Epoetin Alfa - 40k Weekly | 4.3 | 1.95 | Not reported | Not reported | Not reported |
| Epoetin Alfa - 80k Every 3 Weeks | 4.1 | 2.42 | Not reported | Not reported | Not reported |
| Epoetin Alfa - 120k Every 3 Weeks | 4.3 | 2.60 | Not reported | Not reported | Not reported |
| Darbepoetin Alfa - 500 mcg Every 3 Weeks | 4.4 | 2.17 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 2.25
- value
- 4.8
- group Id
- OG001
- spread
- 2.44
- value
- 4.6
- group Id
- OG002
- spread
- 2.53
- value
- 4.6
- group Id
- OG003
- spread
- 2.25
- value
- 4.7
- title
- Fatigue Now
- categories
- measurements
- group Id
- OG000
- spread
- 2.12
- value
- 4.7
- group Id
- OG001
- spread
- 2.40
- value
- 4.7
- group Id
- OG002
- spread
- 2.53
- value
- 4.7
- group Id
- OG003
- spread
- 2.24
- value
- 4.7
- title
- Usual Fatigue
- categories
- measurements
- group Id
- OG000
- spread
- 2.17
- value
- 5.5
- group Id
- OG001
- spread
- 2.54
- value
- 5.6
- group Id
- OG002
- spread
- 2.60
- value
- 5.4
- group Id
- OG003
- spread
- 2.43
- value
- 5.3
- title
- Worst Fatigue
- categories
- measurements
- group Id
- OG000
- spread
- 1.95
- value
- 4.3
- group Id
- OG001
- spread
- 2.42
- value
- 4.1
- group Id
- OG002
- spread
- 2.60
- value
- 4.3
- group Id
- OG003
- spread
- 2.17
- value
- 4.4
- title
- BFI Interference
- denoms
- counts
- group Id
- OG000
- value
- 61
- group Id
- OG001
- value
- 60
- group Id
- OG002
- value
- 58
- group Id
- OG003
- value
- 57
- units
- Participants
- description
- To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule. Brief Fatigue Inventory (BFI) consist of 3 single-item numeric analogue scales on a scale of 0 to 10; and an interference scale formed by 6 single-item numeric scales on a scale of 0 to 10. Higher scores indicate fatigue as bad as you can imagine for fatigue now, usual fatigue and worse fatigue; and completely interferes for BFI interference. Average scores across all time points for fatigue now, usual fatigue, worst fatigue and BFI interference subscale were calculated.
- dispersion Type
- Standard Deviation
- groups
- description
- Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)
- id
- OG000
- title
- Epoetin Alfa - 40k Weekly
- description
- Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)
- id
- OG001
- title
- Epoetin Alfa - 80k Every 3 Weeks
- description
- Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)
- id
- OG002
- title
- Epoetin Alfa - 120k Every 3 Weeks
- description
- Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)
- id
- OG003
- title
- Darbepoetin Alfa - 500 mcg Every 3 Weeks
- param Type
- MEAN
- population Description
- All patients that were evaluable per protocol with QOL data.
- reporting Status
- POSTED
- time Frame
- Weeks 4, 7, 10, 13 and 16
- title
- Quality of Life as Measured by Brief Fatigue Inventory Overall All Follow-up Evaluations
- type
- SECONDARY
- unit Of Measure
- units on a scale
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle